Bayer’s Adempas (riociguat),
a novel treatment for pulmonary
arterial hypertension, has been
given strong support from an
FDA expert panel which voted
unanimously to recommend
approval of the therapy.
Adempas is not approved by the
TGA in Australia at this stage.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Aug 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.